Paper - WANFANG MED ONLINE

You Position: Home > Paper

An overview of biomarkers in Alzheimer's disease

( views:49, downloads:0 )

Author:: No author available

Journal Title:: Acta Pharmaceutica Sinica

Issue:: 5

DOI:: No doi available

Key Word:: 阿尔茨海默病;生物标记物;转化医学

Abstract：阿尔茨海默病(Alzheimer's disease,AD)又称早老性痴呆,是老年人常见的神经退行性疾病之一,其病理特征包括:老年斑、神经元纤维缠结和神经元丢失.生物标记物是指一些可供客观测定和评价的普通生理、病理或治疗过程中的特征性指标,经典的AD的生物标记物如Aβ和磷酸化tau蛋白己被广泛用于AD病人的临床诊断.近年来,由于蛋白组学、基因组学、神经影像等新技术新方法的不断引入,生物标记物的应用范围由疾病的早期诊断拓展到病程的监控以及药物疗效的评价.本文就阿尔茨海默病生物标记物的研究进展进行综述.

Reference

[1]Fabien, Gosselet,Pietra, Candela,Roméo, Cecchelli,etc.[Role of the blood-brain barrier in Alzheimer's disease].[J].2011,27(11).
[2]Zhu L,Xu S,Wang X,etc.Strain- and age-related alteration of proteins in the brain of SAMP8 and SAMR1 mice.[J].2011,23(4).
[3]Isoo N,Morohashi Y,Niimura M,etc.Aph-1 contributes to the stabilization and trafficking of the gamma-secretase complex through mechanisms involving intermolecular and intramolecular interactions[J].2005,280(13).
[4]P Hemachandra, Reddy.Mitochondrial oxidative damage in aging and Alzheimer's disease: implications for mitochondrially targeted antioxidant therapeutics.[J].2006,2006(3).
[5]Hampel H,Weiner M,Blennow K,etc.Cerebrospinal fluid and plasma biomarkers in Alzheimer disease.[J].2010,6(3).
[6]J, Geraghty.Adenomatous polyposis coli and translational medicine.[J].1996,348.
[7]Sorbi S,Caselli R,Perneczky R,etc.Multicenter Standardized 18F-FDG PET Diagnosis of Mild Cognitive Impairment, Alzheimer's Disease, and Other Dementias.[J].2008,49(3).
[8]Otto M,Vanderstichele H,Riemenschneider M,etc.Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias.[J].2003,8(3).
[9]Zinkowski R,De Santi S,Glodzik Sobanska L,etc.Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment.[J].2009,30(5).
[10]Montine KS,Morrow JD,Kaye JA,etc.Suppression of longitudinal increase in CSF F_2-isoprostanes in Alzheimer's disease.[J].2004,6(1).
[11]Pietrzak RH,O'Donnell J,Ellis KC,etc.Understanding failure of visual paired associate learning in amnestic mild cognitive impairment.[J].2011,33(10).
[12]Parkkinen L,Alafuzoff I,Pirttila T,etc.Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.[J].2009,66(3).
[13]D, Galasko,L A, Hansen,R, Katzman,etc.Clinical-neuropathological correlations in Alzheimer's disease and related dementias.[J].1994,51.
[14]Giovanni, Zuliani,Michela Perrone, Donnorso,Cristina, Bosi,etc.Plasma 24S-hydroxycholesterol levels in elderly subjects with late onset Alzheimer's disease or vascular dementia: a case-control study.[J].2011,11.
[15]Rapoport SI,Tapiola T,Zinkowski R,etc.Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231.[J].2002,59(8).
[16]Abraham CR.Reactive astrocytes and alpha1-antichymotrypsin in Alzheimer's disease.[J].2001,22(6).
[17]Blennow K,Strozyk D,Launer LJ,etc.CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study.[J].2003,60(4).
[18]Dickson DW,Potter H,Padmanabhan J,etc.Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons.[J].2006,129(Pt.11).
[19]Zhong Z,Wallin A,Burger K,etc.Increased CSF-BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer's disease.[J].2008,131(Pt.5).
[20]Kivipelto M,Helkala EL,Soininen H,etc.Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study.[J].2001,322(7300).
[21]Selhub J,Rosenberg IH,Seshadri S,etc.Plasma homocysteine as a risk factor for dementia and Alzheimer's disease.[J].2002,346(7).
[22]Colacicco AM,Solfrizzi V,D'Introno A.Alpha-2-macroglobulin gene, oxidized low-density lipoprotein receptor-1 locus, and sporadic Alzheimer's disease.[J].2009,30(9).
[23]Pakrasi S,O'Brien JT.Emission tomography in dementia.[J].2005,26(3).
[24]Blennow K,Hampel H.CSF markers for incipient Alzheimer's disease.[J].2003,2(10).
[25]Masters CL,Pike KE,Mathis CA,etc.Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease.[J].2007,130(Pt.11).
[26]Coon KD,Myers AJ,Craig DW,etc.A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease.[J].2007,68(4).
[27]Ewers M,Wallin A,He P,etc.Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment.[J].2007,64(6).
[28]A, Alzheimer,R A, Stelzmann,H N, Schnitzlein,etc.An English translation of Alzheimer's 1907 paper, "Uber eine eigenartige Erkankung der Hirnrinde".[J].1995,8.
[29]Apostolova LG,Thompson PM.Mapping progressive brain structural changes in early Alzheimer's disease and mild cognitive impairment.[J].2008,46(6).
[30]Hampel H,Burger K,Pruessner JC,etc.Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease.[J].2005,62(5).
[31]M, Mancuso,D, Orsucci,G, Siciliano,etc.Mitochondria, mitochondrial DNA and Alzheimer's disease. What comes first?[J].2008,5(5).
[32].Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group.[J].1900,19.
[33]Ezquerra M,Santacruz P,Oliva R,etc.A novel mutation in the PSEN2 gene (T430M) associated with variable expression in a family with early-onset Alzheimer disease.[J].2003,60(8).
[34]Mizuno T,Mori S,Fukuyama R,etc.Age-dependent change in the levels of Abeta40 and Abeta42 in cerebrospinal fluid from control subjects, and a decrease in the ratio of Abeta42 to Abeta40 level in cerebrospinal fluid from Alzheimer's disease patients.[J].2000,43(3).
[35]Ewers M,Alafuzoff I,Zinkowski R,etc.CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease.[J].2006,129(Pt.11).
[36]Hansson O,Sankaranarayanan S,Buchhave P,etc.Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease.[J].2008,65(8).
[37]Ge Li,Kaspar Rufibach,Joseph F. Quinn,etc.Modeling of Pathological Traits in Alzheimer's Disease Based on Systemic Extracellular Signaling Proteome[J].2011,10(10).
[38]Jack CR Jr,Lowe VJ,Weigand SD,etc.Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease.[J].2009,132(5).